HC Wainwright Comments on Harrow’s Q3 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Research analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Harrow in a research report issued to clients and investors on Thursday, March 19th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $0.21 for the quarter, up from their prior estimate of $0.20. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s FY2026 earnings at $0.56 EPS.

Other research analysts also recently issued reports about the stock. Nomura downgraded shares of Harrow to a “neutral” rating in a research report on Wednesday, March 18th. BTIG Research reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Harrow in a research note on Wednesday, March 18th. Cantor Fitzgerald lowered their price objective on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. William Blair reissued an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Harrow currently has a consensus rating of “Moderate Buy” and an average price target of $71.14.

Harrow Price Performance

HROW stock opened at $35.20 on Monday. Harrow has a one year low of $20.85 and a one year high of $54.85. The firm has a 50-day moving average of $44.02 and a two-hundred day moving average of $43.50. The firm has a market capitalization of $1.31 billion, a PE ratio of -207.05 and a beta of 0.05. The company has a current ratio of 2.20, a quick ratio of 2.06 and a debt-to-equity ratio of 4.67.

Institutional Investors Weigh In On Harrow

Several institutional investors have recently made changes to their positions in HROW. Virtu Financial LLC bought a new stake in shares of Harrow in the 4th quarter valued at approximately $702,000. Invesco Ltd. raised its position in Harrow by 35.7% during the fourth quarter. Invesco Ltd. now owns 145,406 shares of the company’s stock valued at $7,125,000 after acquiring an additional 38,264 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in Harrow during the fourth quarter valued at approximately $801,000. Cetera Investment Advisers lifted its stake in Harrow by 2.6% in the fourth quarter. Cetera Investment Advisers now owns 23,256 shares of the company’s stock valued at $1,140,000 after acquiring an additional 597 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Harrow by 4.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,412 shares of the company’s stock valued at $1,246,000 after acquiring an additional 1,161 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Key Harrow News

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Analyst optimism: HC Wainwright published a positive earnings forecast for Harrow, which can support near-term demand for the shares and help explain upward price pressure. Read More.
• Neutral Sentiment: Short-interest reports are showing zero short interest with NaN/inconsistent changes and 0.0 days-to-cover — the data appears erroneous or not meaningful, so it likely has no material impact on trading. (Multiple routine short-interest entries reported March 23–24.)
• Negative Sentiment: Debt raise — Harrow announced and then priced an add-on offering totaling $50.0M of 8.625% senior unsecured notes due 2030. Adding high-coupon debt increases leverage and interest expense, which can be viewed negatively by equity holders even if proceeds are labeled for growth. Read More. Read More. Read More.
• Negative Sentiment: Major investor selling: reports indicate a roughly $7.8M sale of Harrow shares by a large investor. Large insider/institutional sales can create short-term selling pressure or signal waning conviction. Read More.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.